Gabriele Klingner

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company, has partnered with Liquid Biosciences to potentially add pancreatic cancer detection to its colorectal cancer screening test ColoAlert®. The collaboration aims to develop PancAlert, a screening test that combines genetic and microbiome biomarkers to detect pancreatic cancer in its early stages. Liquid Biosciences will apply its EMERGE AI analysis technology to evaluate biomarkers from Mainz's research program. 'We are excited by the opportunity to collaborate with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection with the goal of being a first-in-class screening test for this deadly form of cancer,' said Guido Baechler, CEO of Mainz Biomed. Pancreatic cancer is a highly aggressive and deadly disease, with a five-year survival rate of just 13%. Early detection is crucial as most cases are diagnosed at a late stage when the cancer has already spread. The collaboration seeks to address this challenge by combining biomarkers for improved early detection, potentially leading to better treatment outcomes and survival rates for pancreatic cancer patients. @mainzbiomed #earlycancerdetection #pancreaticcancer #aidiagnostics

1

Have you joined our poster presentation at #ESMO2024? In this study across various types of cancer, our colleagues, Elisabetta Nale and Julia Bischof, identified the molecular differences between 'hot' and 'cold' tumors, which could help improve immunotherapy treatments. 💡In conclusion, their multi-omic approach revealed the following: 1️⃣ They found known and novel molecular features that discriminate 'hot' and 'cold' tumors pan-cancer 2️⃣ By combining scRNA-Seq from the Broad’s Single Cell Portal with bulk data, our team could differentiate these tumors based on specific immune cell types and their microenvironments 3️⃣ Their findings could play a crucial role in developing precise immunotherapy treatments In case you were not able to attend our poster presentation at ESMO, we have also published the poster online. Make sure to download it below 👇 We look forward to seeing everyone next year in Berlin at ESMO 2025! Download our poster: https://lnkd.in/epHUch85 #esmo2024 #oncology #cancerresearch

36

Our COO, Rudi Schmidt, will speak at the 15th Annual Drug Discovery Forum in Berlin about "What Real-World Data from #aging research can teach us for #AI-based precision medicine in #drug development." #Drugdevelopment faces high attrition rates, and the reproducibility and translatability of preclinical findings to human applications are still limited, resulting in a low return on investment in terms of clinical impact. In his presentation Rudi will focus on how to overcome these challenges and the translational discordance #realworlddata from research in aging and #longevity. Summarizing the latest publications he will outline several conclusions, for example, on state-of-the-art model-informed drug development (MIDD) that combines real-world data of physiology, pharmacology, and disease processes during aging with #artificialintelligence.   Decades of research using genetic and molecular biology tools have unlocked several hallmarks of aging. At the same time, our understanding of embryonic development and cell growth has considerably improved. The mechanisms and pathways related to aging can be targeted for lifestyle as well as for drug interventions. Now this knowledge has to be translated into drug development and clinical applications for age related diseases. 📆 Date: 4th & 5th September 2024 📍 Location: Hotel Palace Berlin (in person event) 🔗 Register https://lnkd.in/d8EFpTuh #DrugDiscovery #health #Innovation #DDIF2024

2.075

18 Kommentare

Don't miss tomorrow's webinar on "Unleashing the Potential of Genomics to Unravel Multiple System Atrophy" featuring Sonja W. Scholz, MD, PhD. 🧬 Dive into the latest breakthroughs in genomic technologies and their impact on MSA research! Register now: https://lnkd.in/gM8EuZb9 #MSA #msaawareness #multiplesystematrophy #raredisease #webinar #healthwebinar #education #research #neuroimaging #rarediseasewebinar #msawebinar #health #healtheducation

3

[NEW Podcast] In this episode we talked with Dr. Stephan Hamperl from Epigenetics Research at Helmholtz Munich about his work on how conflicts between transcription, replication, and R-loop formation influence genome stability in human cells. 🎧 https://bit.ly/3XGHx07 #epigenetics #podcast

8

🔬 Missed yesterday's webinar on "What Makes Modern Lab Software for Pathology & Cytology?" Do not miss out on this second opportunity. But before you dive in, here is a sneak peek into what awaits: The key speakers, Philipp Alexander Maier and Dominik Gerber, discussed the benefits of seamlessly integrating every facet of your pathology lab – from material handling to report generation and reimbursement management into one platform. Topics Covered: ✔️ How to cover all the lab work activities from materials to reports in the most efficient way? ✔️How the continuously upgraded features such as Speech Recognition add value? ✔️ How to reduce errors, save time, and enhance the comfort of your daily activities. Don't miss out on the second chance and mark your calendars: 📅 May 22 (Wednesday): 0800-0820 CEST 🌐 https://lnkd.in/dani5s_q OR 📅 May 23 (Thursday): 1630-1650 CEST 🌐 https://lnkd.in/dx2b7Fah Register now and secure your seat. #Digitization #LabSoftware #SeamlessIntegration #WorkflowManagement

7

#BMBF awards 1.55 Million funding for #DKFZ Panosome GmbH to develop antibody therapies for pancreatic cancer. Panosome GmbH, a DKFZ spinoff, aims to create antibodies targeting the MUC-1 tumor marker, over-expressed in 90% of pancreatic cancers. The #CarboVAST project will also test these antibodies in combination with innovative immunotherapies at the DKFZ German Cancer Research Center, potentially benefiting treatment of other types of cancers. Secretary of State Dr. Jens Brandenburg visited Panosome GmbH to personally hand over the grant notice. This funding marks a significant milestone in the spinoff journey towards effective therapeutics for pancreas cancer. To mark the occasion, a syndicate from members of encourageventures e.V. has announced their commitment to invest in Panosome. Nina Papavasiliou says “Thank you to the DKFZ Management Board for their support, DKFZ Innovation Management and Rainer Wessel for guidance and #encourageventures for their willingness to help fundraise for this grant (which unlike academic grants requires 20% cofinancing).” The initiative highlights the importance of #biotechnology #startups in advancing medical treatments and is a significant step forward in personalized medicine. 🌟 #CancerResearch #Biotechnology #Innovation #Healthcare #PancreaticCancer #PanosomeGmbH https://lnkd.in/eEvEeDF8 https://lnkd.in/eMN_rfd4 /bjcmp

246

21 Kommentare

#𝗞𝗲𝘆 𝘁𝗼 𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 #𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱: Some cancer drugs cause severe side effects because they are not working accurately enough. A team at the University of Würzburg led by biochemist Caroline Kisker has now discovered why. The small protein ubiquitin is involved in almost every cellular process in our body: it orchestrates the stability and function of the vast majority of proteins. When it binds to other proteins, they are often released for degradation. However, this labelling can also be reversed by special enzymes. The enzyme USP28, for example, is known to stabilise proteins that are important for cell growth and division – these can also play an important role in cancer growth. 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗮𝘃𝗲𝘀 𝘁𝗵𝗲 𝗪𝗮𝘆 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀: https://lnkd.in/e6xCQDTF Julius-Maximilians-Universität Würzburg, Jonathan Patzke, Florian Sauer, Radhika Nair, Erik Endres, Ewgenij Proschak, Dr. Victor Hernandez-Olmos, Christoph Sotriffer

2